Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV
The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
Precision BioSciences, Inc. (NASDAQ:DTIL) revealed initial results from the first administration of PBGENE-HBV in cohort 1, ...
News Medical2d
Nanoparticles and Advanced Analytics Accelerate Vaccine Development
Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...
Precision BioSciences announces initial results from ELIMINATE-B trial
Precision BioSciences (DTIL) announced initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ...